Content about Print

SUPPLIER NEWS — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the “next generation pseudoephedrine product,” Nexafed is a 30 mg PSE hydrochloride tablet that utilizes Acura’s trademarked Impede technology. 


Change was in the air again this year at Sam’s Club as the warehouse club division welcomed yet another CEO and head merchant combination. In early 2012, Rosalind Brewer became president and CEO, and Charles Redfield was named EVP merchandising. The change could have had suppliers saying, “here we go again,” due to Sam’s history of senior leadership turnover. Instead, the transition was apparently painless for the 67% of survey respondents who sell products to Sam’s.

Men’s shaving/grooming and deodorants may continue to dominate the male grooming segment, but there’s no doubt that guys are increasingly taking greater notice of skin care products — a trend that is expected to gain greater momentum going forward.


WHEELING, Ill. — “When you create something for [our various retail concepts], you are creating a new experience and environment that makes us different than our competitive set. Exclusivity of the experience is a large differentiator.” That was a key message that keynote retail speaker Shannon Curtin, Walgreens divisional VP and GMM for beauty, personal care and seasonal, had for attendees of the Oct. 17 Mack Elevation Forum, held here at the Westin Chicago North Shore Hotel.

Walgreens is the newest to jump into the loyalty game. Still, its Balance Rewards managed to sign up 16 million members within just two weeks of its mid-September launch.

In many ways, Balance Rewards represents some of the best thinking in customer loyalty. There’s a better-health incentive linked to the Walk with Walgreens program. There are complementary health offerings tied to participation. It is mobile-enabled and ties into its multichannel strategy. Points don’t expire. And the data from the program will help inform every facet of Walgreens’ business.

Sales of color cosmetics lost some of its shimmer during the recession as beauty mavens reduced purchase cycles, traded down to value brands and cut back on experimenting with new products. However, consumers are returning to the category, which is likely to spell strong sales for spring and beyond.


CVS/pharmacy certainly is the leader in terms of how to translate reams of shopper data into programs that drive profitable results. It’s been at it for almost 15 years, and its 70 million active cardholders makes for the largest loyalty program in retail pharmacy.

In a major nod to the program’s success, 67% of CVS transactions and 82% of all front-store sales are tied to ExtraCare, and card members buy 85% more items per trip versus nonmembers.



Target and CVS are some of the first retailers to group adult multivitamins and supplements available in gummy format into one 4-ft. set. The idea is to make shopping vitamins and supplements easier. For the 12 weeks ended Sept. 9, SymphonyIRI Group tabulated $202 million in sales of multivitamins, up slightly by 0.8%, across food, drug and mass (excluding Walmart).

Retailers are facing challenges in a rapidly changing photo-processing category. One huge shift has been in category leadership. One dominant brand is no longer directing — and pouring advertising dollars into — the category, so retailers need to take a more active role in marketing 
photo processing. 


Another challenge is what to market. Consumers are still ordering prints, but they are increasingly viewing, manipulating and saving their photos online.


The battle to capture and retain customers in a world where price, convenience and even customer service have become commoditized is in full swing. “The risk is you end up in a loyalty war [where] companies begin to use the loyalty scheme or the loyalty component of [the card] as another form of price escalation,” warned Bryon Pearson, president of LoyaltyOne and contributing editor to Colloquy, a magazine that has covered the loyalty marketing industry since 1990. “The intelligence that sits behind these programs is where the real value is,” he said.

While there is still plenty of room for improvement, a growing number of patients have either already received or plan to receive a flu shot this year compared to one year ago. According to an online survey of more than 900 AccentHealth viewers conducted in September, 57% of patients have received or plan to receive a flu shot this year, versus 53% in 2011. 


To see more Patient Views, click here.

FDA approves cardiovascular drug

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain. Actavis announced the approval of diltiazem hydrochloride extended-release capsules.
The drug is a generic version of Valeant’s Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.